Putnam Investments’s Theravance Biopharma TBPH Stock Holding History

Putnam Investments’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-102,102	Closed	-$1.15M	–	1206
2022 Q4	$1.15M	Sell	102,102 -54	-0.1%	-$568	﹤0.01%	819
2022 Q3	$1.04M	Sell	102,156 -1,852	-2%	-$17.4K	﹤0.01%	845
2022 Q2	$943K	Sell	104,008 -1,286	-1%	-$11.8K	﹤0.01%	873
2022 Q1	$1.01M	Buy	+105,294	New	+$1.03M	﹤0.01%	900
2016 Q1	–	Sell	-74,725	Closed	-$1.23M	–	1457
2015 Q4	$1.23M	Hold	74,725	–	–	﹤0.01%	1109
2015 Q3	$822K	Buy	+74,725	New	+$951K	﹤0.01%	1220

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Putnam Investments's TBPH Position: Q1 2023 in Review

Putnam Investments sold out of Theravance Biopharma (TBPH) in Q1 2023, closing a stake of 102,102 shares — an estimated $1.15M sold.

Putnam Investments first reported a position in TBPH in Q3 2015 and held it in 6 quarters. The position peaked at $1.23M in Q4 2015. 113 funds tracked by Wall St. Rank hold TBPH as of Q1 2023.

Putnam Investments reported no remaining Theravance Biopharma position as of Q1 2023 after selling out during the quarter.
Putnam Investments sold 102,102 Theravance Biopharma shares in Q1 2023, an estimated $1.15M.
Putnam Investments first reported a position in Theravance Biopharma in Q3 2015 and held it in 6 quarters.
Putnam Investments's Theravance Biopharma position peaked at $1.23M in Q4 2015.
113 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2023.

Based on Putnam Investments's 13F filing for Q1 2023, filed 22 May 2023.